Cipher Pharmaceuticals Inc (TSE:CPH) – Cormark dropped their Q1 2017 earnings per share (EPS) estimates for Cipher Pharmaceuticals in a note issued to investors on Monday. Cormark analyst D. Novak now forecasts that the brokerage will post earnings of $0.07 per share for the quarter, down from their prior forecast of $0.10. Cormark also issued estimates for Cipher Pharmaceuticals’ Q2 2017 earnings at $0.04 EPS, Q3 2017 earnings at $0.08 EPS and FY2017 earnings at $0.22 EPS.

CPH has been the subject of several other research reports. GMP Securities lowered Cipher Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, August 11th. TD Securities reaffirmed a “buy” rating and issued a C$7.50 price objective on shares of Cipher Pharmaceuticals in a report on Thursday, August 11th.

Shares of Cipher Pharmaceuticals (TSE:CPH) opened at 4.99 on Tuesday. The company’s market cap is $130.71 million. The stock’s 50 day moving average price is $5.24 and its 200 day moving average price is $6.59. Cipher Pharmaceuticals has a 12-month low of $4.81 and a 12-month high of $8.18.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Receive News & Stock Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related stocks with our FREE daily email newsletter.